Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Lingamneni Anila
EVP, Chief Technology Officer
Haemonetics Corporation
US, Boston [HQ]
CIK
1808414
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
14,495
Price per Share :
$73.49
Equivalence :
$1,065,237.55
Transaction History
-
S14,495 Shares After TransactionValue : $1,304,550.00Sold $207,450.00Transaction Date : 09/11/23
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated June 2, 2023 (fully executed as of June 5, 2023).#2 This number includes unvested restricted stock units previously reported.
-
A28,825 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.
-
F23,546 Shares After TransactionValue : $2,254,058.58$505,358.67Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.
-
S12,295 Shares After TransactionValue : $1,168,025.00Sold $218,975.00Transaction Date : 05/06/24
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated June 2, 2023 (fully executed as of June 5, 2023).#2 This number includes unvested restricted stock units previously reported as well as 289 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024.
-
S21,410 Shares After TransactionValue : $1,926,900.00Sold $192,240.00Transaction Date : 07/11/24
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).#2 This number includes unvested restricted stock units previously reported.